Background:
Studies showing the potential predictive value of the actin-binding protein gelsolin, in critically ill patients are scarce. Moreover, even up to now a rapid automated measurement of gelsolin has still remained a challenge. Therefore, we developed and validated an automated serum gelsolin immune turbidimetric assay for possible clinical use.
Methods: Validation of serum gelsolin assay was performed on a Cobas 8000/c502
analyzer (Roche) according to the second edition of Eurachem guidelines. Furthermore, we also studied the diagnostic value of serum gelsolin in sepsis when investigating sera of septic (n = 25), systemic inflammatory response syndrome (SIRS; n = 8) and control patients (n = 14). We compared our previously published Western blot data with those of the new turbidimetric assay.
Results:
The sample volume was 7 μL and the assay time was 10 minutes. The detection limit was 0.72 mg/L, intra-and inter-assay imprecision remained in most cases less than 5% expressed as CV. Recovery was found to be 84.56%-93.52% and linearity study gave an appropriate correlation coefficient by linear regression analysis (r 2 = .998). Septic patients exhibited lower (P = .015) first-day serum gelsolin levels than SIRS patients, which confirmed our previous Western blot results. The determined cut-off point for serum gelsolin was 14.05 mg/L (sensitivity: 75%; specificity: 60%)
when investigating its diagnostic value in sepsis.
Conclusion:
Based on the results, our immune turbidimetric measurement offers a rapid and accurate quantitation of gelsolin in human serum samples. Serum gelsolin seems a promising additional diagnostic marker of sepsis which has to be further investigated.
K E Y W O R D S
automation, diagnostic marker, immune turbidimetry, sepsis, serum gelsolin se-GSN is suggested to be involved in the modulation of inflammatory processes, too. 4, 5 In severe systemic inflammation, as sepsis, se-GSN levels drop significantly. Gelsolin is part of the so called actin scavenger system and therefore a possible reason for its decrease is the excessive release of filamentous actin into the circulation due to massive cell injury, 3, 6, 7 and-in case of bacterial infections-the appearance of high amounts of bacterial wall lipids as well. 4, 5 
| INTRODUCTION

| MATERIALS AND METHODS
| Reagents, assay conditions
The immune turbidimetric assay for se-GSN measurement was per-
formed on an open developmental channel of the c502 module of a
Cobas 8000 analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
Because of the unavailability of any commercial GSN calibra- 
| Validation of the GSN assay
The second edition of Eurachem guidelines 15 was applied for the vali- For recovery study both of the low and the high GSN concentration samples were spiked with purified human GSN. L, low GSN concentration sample; M, middle GSN concentration sample; H, high GSN concentration sample.
T A B L E 1 Intra-, inter-assay precision and recovery of serum gelsolin (GSN) assay Intra-and inter-assay imprecisions were estimated by three different sera (low, middle and high GSN concentrations). For the assessment of intra-assay variability, 15 parallel measurements were performed on the same day, while for inter-assay variability two parallel measurements were executed on 10 consecutive days.
For recovery studies, aliquots of both the low and high GSN concentration serum samples were spiked with two different amounts of human purified GSN standard, thereafter recovery (%) was calculated from the measured (n = 15/level) and calculated values. 
| Clinical evaluation of se-GSN assay
We analyzed a representative number of sera of septic, systemic inflammatory response syndrome (SIRS) and control patients by immune turbidimetry, which had already been investigated by
Western blot measurements in our previously published study.
7
The validated immune turbidimetric GSN assay was compared to previous Western blot method by Bland-Altman plot procedure.
Western blot and immune turbidimetric results were also studied by receiver operating characteristic curve (ROC) analysis.
Regarding the study protocol, the applied sepsis definitions and patients' enrollment we refer to our latest publication. 
| Statistical analysis
For statistical analysis IBM SPSS Statistics for Windows, Version 22
and Origin Pro 8 softwares were used. Kruskal-Wallis, Mann-Whitney and chi-squared tests were performed for investigating differences between patient groups. Diagnostic values were assessed by receiver operating characteristic (ROC) curves. Bland-Altman plot was used for method comparison. Changes in the results were considered to be statistically significant at P < .05. to be 0.47 mg/L, 0.72 mg/L and 1.99 mg/L, respectively. Coefficient of variation remained below 5% in most of the cases during the intraand inter-assay variability measurements. Recovery varied between 84.56%-93.52% when investigating four different ranges (Table 1) .
| RESULTS
| Validation data
Linearity study gave an appropriate coefficient by the linear regression analysis (r 2 = .998) after comparing calculated and measured GSN concentrations regarding 10 different dilutions ( Figure 1B ).
| Stability studies
GSN levels remained almost unchanged (96.70%-117.36%) during the 10-day stability period, and no considerable differences were observed even throughout five repeated freezing-thawing cycles (Table 2 ). Table 3 illustrates the main demographic and laboratory parameters of the enrolled patients. First-day clinical scores (APACHE II, SAPS II, SOFA) were proven to be significantly (P < .05) higher among septic than among SIRS patients. Septic patients showed higher levels of serum procalcitonin (PCT) (P < .001) and high-sensitivity C-reactive protein (P < .01) than non-septic critically ill patients. Septic and SIRS patients exhibited significantly lower first-day serum GSN levels than controls when measured by immune turbidimetry (P < .001) ( Figure 2A , Table 3 ). Furthermore, serum GSN levels were lower in septic than in SIRS patients (P = .
| First-day serum GSN levels of septic, SIRS and control patients
015). Previous Western blot results
showed a similar pattern to those of immune turbidimetry except that among the limited number of subjects there was no significant difference between serum GSN levels of septic and SIRS patients (Table 3) .
Bland-Altman plot defined a bias of 0.26 and an agreement range from −0.79 to 1.09 units when comparing GSN levels of septic, SIRS and control patients measured by previous Western blot method 7 and by the new turbidimetric assay ( Figure 2B ).
| Diagnostic value of serum GSN levels in sepsis
We also investigated whether first-day se-GSN measured by immune turbidimetry could differentiate between the septic and SIRS states.
Area under the curve (AUC) value for se-GSN was found to be 0.79, the determined cut-off point was 14.05 mg/L (sensitivity: 75%; specificity: 60%), ( Figure 3A ). Western blot measurement offered a lower AUC (0.63) for se-GSN when compared to immune turbidimetry.
Serum PCT and high-sensitivity C-reactive protein (hs-CRP) had an AUC of 0.98 and 0.85, respectively ( Figure 3B ). Data are expressed as medians (25%-75% percentiles), except for age (median [min-max]). Level of significance is set at P < .05. not commonly automated. Cobas 8000 analyzer enables an excellent precision and it is easily connectable to the laboratory informational system (LIS) as well as to the hospital information system (HIS).
| DISCUSSION
Former study of Christensen et al 14 presented an immune turbidimetric assay for se-GSN on Cobas Mira Plus which offered a slightly lower (4%) total imprecision when compared to our method and a detection limit of 2.7 U/L. However, due to unexpected GSN calibrator and control stability problems, this former assay is no longer available. 18 presented an immunonephelometric measurement for plasma GSN, but they did not offer any validation data about the assay.
Study of Dahl et al
We found se-GSN as a stable protein maintaining its concentration constant at +4°C for 10 days and even throughout five repeated freezing-thawing cycles. We did not find any significant differences between serum and plasma levels of GSN (when using sodium citrate tube). However, we do not consider EDTA containing tubes for sample collection when measuring GSN levels because plasma GSN levels drop significantly in a short time (data not shown). One possible reason for that could be that EDTA binds Ca 2+ ions more strongly than sodium citrate, in addition, it chelates other metal ions too, 19 which results in the destabilization of the GSN domains.
We could confirm the previously published 7 diagnostic capability of first-day se-GSN levels in sepsis by immune turbidimetry, too. Previous Western blot results showed slightly higher GSN levels in all patients when compared to those of our new GSN assay. That difference could be attributed to the fact that Western blot is a more user-dependent method than immune turbidimetry. Similar to our results, studies of Wang et al 6 also found significantly lower first-day se-GSN levels in septic patients when compared to non-septic critically ill patients.
We acknowledge that our study has limitations. Currently, there is no commercially available human GSN calibrator and control for immune turbidimetry. To handle this difficulty we applied highly purified human GSN expressed in E. coli as a calibrator, and we used pooled Therefore, any protein marker investigations focusing on sepsis-
including serum GSN studies-should also be performed with respect to the Sepsis-3 criteria.
Immune turbidimetric measurement offers a rapid an accurate way to detect GSN in human serum samples. The diagnostic performance of serum GSN should give additional information for clinicians, and its possible further clinical use has to be further investigated.
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